This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.
|The DDDs are generally based on the treatment or diagnosis of endocrine disorders.|
H02 CORTICOSTEROIDS FOR SYSTEMIC USE
As a main rule, systemic corticosteroids should be classified in this group. There is, however, one exception: M01BA - Antiinflam-matory/antirheumatic agents in combination with corticosteroids.
Corticosteroids for local oral treatment, see A01AC.
Enemas and rectal foams for local treatment of e.g. ulcerative colitis, see A07E.
Corticosteroids for topical use, see D07.
Combined corticosteroid preparations for local treatment of acne, see D10AA.
Corticosteroids in combination with antiinfectives/antiseptics for local treatment of gynecological infections, see G01B.
Corticosteroids for nasal use, see R01AD.
Corticosteroids for inhalation, see R03BA.
Corticosteroids, eye/ear preparations, see S.
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Only plain preparations are classified in this group. The group also includes corticosteroid preparations for local injection.
Oral formulations used solely in local treatment are classified in A07EA.
|Depot preparations may have different DDDs, compared to other formulations, due to different indications.|
Last updated: 2016-12-19